Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Bofanglutide (GZR18)

Bofanglutide (GZR18)

GLP-1 · s.c. every 2 weeks · Gan & Lee

Data cut 12 November 2026 · page built 16 November 2026 · 12 trial arms · 4 trials with results · 9 registered trials · see on the pipeline board

Summary

Also known as
Gan & Lee
Mechanism
GLP-1
Route
s.c. every 2 weeks
Company
Gan & Lee
Highest development stage
phase 3
Status (as of data cut)
Phase 3 GRADUAL-1 positive (48 mg every 2 weeks: −18.5 % at 52 weeks); US phase 2; once-monthly GRADUAL-3 started verify
Next milestone
NDA in China

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 GRADUAL-1 (52 weeks); GRADUAL-3 once-monthly maintenance after GRADUAL-1: weight +0.41 % / −0.12 % vs +8.52 % with placebo over 24 weeks (topline release, November 2026)Gan & Lee release, 4 Nov 2026
T2D2 phase 3 ongoingPhase 3 ongoing
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
Phase 2b CTR2023169512 mg Q2Wobesity china3052——−11.2 % vs −1.0 %
estimand not specified
—————0.0—press release
Phase 2b CTR2023169518 mg Q2Wobesity china3053——−13.2 % vs −1.0 %
estimand not specified
—————0.0—press release
Phase 2b CTR2023169524 mg Q2Wobesity china3052——−14.2 % vs −1.0 %
estimand not specified
—————0.0—press release
Phase 2b CTR2023169548 mg Q2Wobesity china3064——−17.3 % vs −1.0 %
estimand not specified
—————0.0—press release
Phase 2b CTR2023169524 mg QWobesity china3053——−17.8 % vs −1.0 %
estimand not specified
—————0.0—press release
Phase 2b CTR20232069 (vs semaglutide)12 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−1.9——————press release
Phase 2b CTR20232069 (vs semaglutide)18 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−2.3——————press release
Phase 2b CTR20232069 (vs semaglutide)24 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−1.9——————press release
Phase 2b CTR20232069 (vs semaglutide)24 mg QW vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−2.3——————press release
US Phase 2 (NCT06737042)48 mg Q2W vs tirzepatide 15 mg QW (open-label active comparator): weight -16.93 %obesity36326——−15.2 %
estimand not specified
———————press release
GRADUAL-1 (NCT06728124)24 mg Q2Wobesity china52640——−15.1 % vs −1.1 %
estimand not specified
———————press release
GRADUAL-1 (NCT06728124)48 mg Q2Wobesity china52640——−18.5 % vs −1.1 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (17)
  • 12 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 12 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 18 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 18 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 24 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 24 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 48 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 48 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 24 mg QW · weight_unsp · press release
    In the QW 24 mg group, participants experienced a weight reduction of 17.78% (1.01)
  • 24 mg QW · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 12 mg Q2W · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 18 mg Q2W · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 24 mg Q2W · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 24 mg QW · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 24 mg Q2W · weight_unsp · press release
    achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
  • 48 mg Q2W · weight_unsp · press release
    achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
  • 48 mg Q2W · weight_unsp · press release
    the 48 mg bofanglutide injection group achieved an average weight loss of 15.18%

Registered trials (9)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
BALANCE-OBS
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
ObesityPhase 3not yet recruiting2026-09 → 2027-12352not yet recruitingNCT07622810
NCT07628985
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
T2DPhase 3not yet recruiting2026-09 → 2027-10374not yet recruitingNCT07628985
NCT07493057
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
Sleep apnoeaPhase 3recruiting2026-04 → 2027-11140recruitingNCT07493057
NCT07501832
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy
Sleep apnoeaPhase 3recruiting2026-04 → 2028-09140recruitingNCT07501832
GZR18-BWM-303
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
ObesityPhase 3completed2026-01 → 2026-09224Completed; results not in the atlas yetNCT07292441
NCT07150975
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
ObesityPhase 3recruiting2025-09 → 2027-06420recruitingNCT07150975
Optimum 1
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
T2DPhase 3completed2025-02 → 2026-07274Completed; results not in the atlas yetNCT06777238
Optimum 2
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
T2DPhase 3completed2025-02 → 2026-091133Completed; results not in the atlas yetNCT06778967
NCT06728124
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
ObesityPhase 3completed2024-12 → 2026-03640Completed; results not in the atlas yetNCT06728124

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Bofanglutide (GZR18). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/bofanglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.